

PRESS-RELEASE

Neobiomics AB and ExCEED Orphan s.r.o. announce an extended partnership for ProPrams® in Estonia, Latvia and Lithuania

Stockholm, Sweden, 17 Nov 2022 – Neobiomics AB and ExCEED Orphan s.r.o. have agreed to extend their partnership towards new territories within the Baltics. After collaborating over an exclusive distribution agreement for 14 countries in Central and Eastern Europe (CEE), the extended agreement will now also include Estonia, Latvia, and Lithuania. The agreement includes marketing and sales of Neobiomics' proprietary product ProPrams® and is in effect immediately.

Neobiomics is a Sweden-based company specializing in the area of neonatal and child health care and ExCEED Orphan s.r.o. is a Czech Republic-based company focused on products for the treatment of rare diseases.

Dr. Stefan Johansson, CEO, and Founder of Neobiomics regards the agreement as another important step for ProPrams® market expansion: *"We at Neobiomics are very happy to have found such a good partner in ExCEED Orphan. Their successful introduction of ProPrams® into the CEE region makes us confident about a quick uptake of ProPrams® also in the Baltics."*

Jiri Hermanek, CEO and Founding Partner of ExCEED Orphan comments: *"ProPrams®, Neobiomics' high-quality multi-strain food supplement for premature newborns, has proven valuable for our portfolio in the CEE countries. We are now looking forward to bringing ProPrams® to the Baltic countries together with Neobiomics."*

About Neobiomics

Neobiomics AB, founded in 2016 by Stefan Johansson and Philipp Novak, is an alumni member of the Innovation Incubator at Karolinska Institutet Innovation AB. The first product ProPrams® is a high-quality multi-strain food supplement manufactured by Chr. Hansen is a worldwide leader in manufacturing bacterial cultures. ProPrams® is now available in a majority of European countries and continues its geographical expansion within Europe.

About ExCEED Orphan s.r.o.

ExCEED Orphan s.r.o. was founded in 2018 by 5 rare disease experts from multiple CEE countries. The company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field. The portfolio of ExCEED Orphan includes products in therapeutic areas like hematology, neurology, immunology, and metabolic diseases.

For further information, please refer to www.neobiomics.eu and www.exceedorphan.com